January 06, 2021
Article
January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.
December 07, 2020
Video
Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.
December 01, 2020
Video
Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.
October 23, 2020
Video
Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.
October 16, 2020
Video
Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.
October 15, 2020
Video
Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.